Steffan Nawrocki, PhD
The major focus of the Nawrocki Lab is the evaluation of molecular mechanisms of action of novel experimental cancer therapeutics with an emphasis on targeting protein degradation. Dr. Nawrocki has received several prestigious honors including awards from the International Myeloma Foundation, the Leukemia & Lymphoma Society, and the Voelcker Foundation.
Degree(s)
- PhD: Cancer Biology/Toxicology: University of Texas M.D. Anderson Cancer Center, Houston, Texas
- MS: Biological Sciences - Toxicology: University of Memphis, Tennessee
- BS: Biology: University of Mississippi, Oxford, Mississippi
mechanisms of action of experimental anticancer agents, enhancing cancer cell death and overcome drug resistance, novel therapeutic agents that target protein degradation pathways (including proteasome inhibitors, autophagy inhibitors, and therapies that induce endoplasmic reticular stress), autophagy and its regulation of drug resistance and metastatic pathogenesis, mechanisms of action of oncolytic virus therapy